Price$18.00-0.49 (-2.65%)
01:45 PM07:45 PM
News · 26 weeks37-44%
2025-12-142026-06-07
Mix3090d
- Insider14(47%)
- SEC Filings7(23%)
- Other5(17%)
- Earnings2(7%)
- Analyst1(3%)
- Leadership1(3%)
Latest news
25 items- PRStevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight ManagementThe fixed-dose, multi-use pen injector platform features a pull-push mechanism designed to reduce use error while supporting delivery volumes up to 0.75 mL Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, today introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608096966/en/Deora™ is Stevanato Group's multi-use, fi
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- PRStevanato Group Announces Results of Ordinary and Extraordinary Shareholders' MeetingAll Resolutions Proposed to Shareholders Passed Stevanato Group S.p.A. (NYSE:STVN) (the "Company"), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that all resolutions proposed to the shareholders at the Ordinary and Extraordinary Meeting of Shareholders ("Shareholders' Meeting") held virtually on May 26, 2026, have passed. Details of the resolutions submitted to, and approved by, the Shareholders' Meeting are included in the explanatory report prepared by the Board of Directors of the Company, which is available on the Company's corporate website at https://ir.steva
- ANALYSTWolfe Research resumed coverage on Stevanato Group S.p.A. with a new price targetWolfe Research resumed coverage of Stevanato Group S.p.A. with a rating of Outperform and set a new price target of $21.00
- SECSEC Form SD filed by Stevanato Group S.p.A.SD - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form SCHEDULE 13G filed by Stevanato Group S.p.A.SCHEDULE 13G - Stevanato Group S.p.A. (0001849853) (Subject)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- PRStevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026- The Company Maintains Fiscal 2026 Guidance - Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2026. First Quarter of 2026 Highlights (comparisons to prior-year period) For the first quarter of 2026, revenue increased 7% (10% on a constant currency basis) to €273.6 million, with high-value solutions representing 47% of total revenue. Gross profit margin increased 30 basis points to 27.5%. Adjusted EBITDA margin increased 150 basis points to 23.9%. Diluted earnings per shar
- PRStevanato Group to Participate in Three Upcoming Investor ConferencesStevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences: Tuesday, May 12, at 8:00 a.m. (PT) - Bank of America Global Healthcare Conference in Las Vegas, NV Tuesday, June 2, at 2:40 - 3:10 p.m. (CT) – William Blair Growth Stock Conference in Chicago, IL Thursday, June 4, at 9:55 - 10:25 a.m. (EDT) – Jefferies Healthcare Conference in New York, NY A live webcast for each event will be available on the Company's website at www.stevanatogroup.com under the "Investors" sec
- PRStevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter 2026 on Thursday, May 7, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Thursday, May 7, 2026, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-registrat
- INSIDERSEC Form 3 filed by new insider Santel Luciano3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Magistretti Elisabetta3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Flynn Karen3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Federici William J3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Spinazzi Alvise3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Morel Donald E Jr3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Stevanato Franco3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Stevanato Sergio3/A - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lin Sue-Jean3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Balachandran Madhavan3 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERSEC Form 3 filed by new insider Stevanato Sergio3 - Stevanato Group S.p.A. (0001849853) (Issuer)
STVN FAQ
8 questionsWhat does Stevanato Group S.p.A. do?
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.Where does STVN stock trade?
Stevanato Group S.p.A. (STVN) is listed on NYSE.What sector and industry is STVN in?
Stevanato Group S.p.A. operates in the Health Care sector, Medical/Dental Instruments industry.When did Stevanato Group S.p.A. go public?
Stevanato Group S.p.A. (STVN) completed its IPO in 2021.Does STVN pay a dividend?
Yes. STVN's next ex-dividend date is 2026-06-11 with a declared cash dividend of $0.04 per share, payable 2026-07-29.What are analysts saying about STVN?
Stevanato Group S.p.A. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform with a $2100.00 price target on 2026-06-02. Recent price targets range from $2100.00 to $3300.00.What companies are similar to STVN?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare STVN side-by-side with any of them on Quantisnow.How can I track STVN on Quantisnow?
Quantisnow aggregates Stevanato Group S.p.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STVN to receive live email and push alerts on every new disclosure.